New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:56 EDTBONEBacterin says study cites potential for OsteoSponge SC
Bacterin International announced that The Journal of Foot & Ankle Surgery has published a study on the "Role of Demineralized Allograft Subchondral Bone in the Treatment of Shoulder Lesions of the Talus: Clinical Results with Two-Year Follow-up." This study followed the use of OsteoSponge SC in the treatment of medial shoulder lesions of the talus, with positive clinical outcomes at 2 years post-op. The OsteoSponge SC procedure has the potential to address defects associated with subchondral bone pathology, which includes failed microfracture procedures and other treatment modalities. The total estimated US market for knee and ankle microfractures in 2014 is approximately 410,000 procedures. Bacterin is the only company in this market with a product specifically positioned to address repair of the subchondral bone in treating these defects, and has demonstrated clinical evidence to support the unique approach.
News For BONE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 17, 2015
16:39 EDTBONEBacterin sees FY15 revenue $40M-$42M, consensus $35.18M
Subscribe for More Information
16:37 EDTBONEBacterin reports Q4 EPS (49c), one estimate (35c)
Subscribe for More Information
March 16, 2015
07:33 EDTBONEBacterin announces contract extension with Novation
Bacterin International Holdings announced that it has extended its contract with Novation for an additional year. The extension will allow Bacterin to continue to supply Novation members with OsteoSponge, OsteoSelect DBM Putty, and other proprietary Bacterin allografts. Novation develops and manages competitive contracts with more than 700 suppliers. As a biologic supplier, Bacterin is one of only three companies with a contract for demineralized bone matrix technologies and one of four allograft suppliers. This gives Bacterin a competitive advantage in comparison to many biologic providers that do not have an agreement with Novation. Since entering into a contract in 2012, Bacterin has worked closely with Novation in several areas including helping to drive contract utilization with its members, adding value for the facility and their patients, and helping its members recognize savings without compromising safety or quality. In 2014, approximately 25% of Bacterin's revenues were generated by Novation members.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use